| Literature DB >> 26854265 |
Gwenalyn Garcia1, Jean Paul Atallah1.
Abstract
Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.Entities:
Keywords: Chemotherapy; hemolytic uremic syndrome; thrombotic microangiopathy; thrombotic thrombocytopenic purpura
Mesh:
Substances:
Year: 2016 PMID: 26854265 DOI: 10.1177/1078155216628324
Source DB: PubMed Journal: J Oncol Pharm Pract ISSN: 1078-1552 Impact factor: 1.809